first patented BACE1 protease inhib. of series
Ph. II/III in Alzheimer’s, discontinued (tox.)
from phenotypic screen and SBDD
J. Med. Chem., Feb. 15, 2021
Shionogi Pharmaceutical, Osaka, JP
Atabecestat (JNJ-54861911)
9. The Shionogi BACE1 aspartyl protease inhibitor, atabecestat (JNJ-54861911) is an oral, brain-penetrant compound that was advanced into the EARLY Ph. IIb/III clinical trial for treatment of preclinical Alzheimer’s…